MarginsXMarginsX
Home › Markets › Health Care › TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP)

TNXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.88
-4.32% on the day
Market cap
$56.0M
Micro cap
Revenue · 2025
$13.1M
+29.8% on 2024
Net income · 2025
-$124.0M
-946.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/0001999371-26-005730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTNXP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001430306
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$13.1M
Net income-$124.0M
Operating income-$125.7M
Net margin-946.2%
Operating margin-959.1%
Revenue growth+29.8%
Cash$207.6M
Total assets$277.2M
P/E (computed)Net income was not positive
P/S (computed)4.3×

Warning signs

Cash runway
11.8 months
$162.8M cash at September 30, 2026
Share count, 1 year
+65.0%
2025-11-10 to 2026-11-06 · +260623.6% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
$459K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-09
Cash and burn$162.8M cash; operating cash flow -$41.3M a quarter.Report 2026-09-30
Shares outstanding19,431,516 (2026-11-06); 11,776,542 a year earlier; 23,849,341 three years earlier. 3y figure adjusted for splits (1-for-3200 overall).Cover page 2026-11-06
Reverse splits, 3 years2; latest 1-for-100 on 2025-02-05Source 2025-02-05
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2025-12-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Iselin, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $459K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$17.2M-$53.3M-$41.1M$162.8MNo debt tags$43.0M10-Q 2026-11-09
Q2 2026
2026-06-30
$13.5M-$40.6M-$42.2M$176.2MNo debt tags$29.1M10-Q 2026-08-10
Q1 2026
2026-03-31
$6.9M-$40.2M-$42.3M$185.5MNo debt tags$17.6M10-Q 2026-05-11
Q4 2025
2025-12-31
$5.4M-$46.9M-$39.6M$207.6MNo debt tags$13.1M10-K 2026-03-12
Q3 2025
2025-09-30
$3.3M-$32.0M-$28.8M$190.1MNo debt tags$10.3M10-Q 2026-11-09
Q2 2025
2025-06-30
$2.0M-$28.3M-$14.8M$125.3MNo debt tags$9.8M10-Q 2026-08-10
Q1 2025
2025-03-31
$2.4M-$16.8M-$16.6M$131.7MNo debt tags$10.0M10-Q 2026-05-11
Q4 2024
2024-12-31
$2.6M-$22.1M-$14.6M$98.8M$8.7M$10.1M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52025-12-29
Latest annual report
ANNUAL REPORT
10-K2026-03-12
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-09
Latest current report8-K2026-11-13
Latest proxy
DEFINITIVE PROXY STATEMENT
DEF 14A2026-03-30

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-36.5%
1 month-50.9%
3 months-75.9%
Year to date-80.7%
1 year-81.4%
From 52-week high-84.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XBITXBiotech Inc.$1.85-5.37%$56.4M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
BOLDBoundless Bio Inc.$2.41-3.60%$56.9M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
CINGCingulate Inc.$3.75-12.79%$54.5M
INCRIntercure Ltd.$3.63-4.22%$54.5M
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M
XLOXilio Therapeutics Inc.$7.70-3.08%$54.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier